Table 4.

Relationship between BRCA1 and BRCA2 gene methylation and clinical and pathological characteristics of breast cancer patients

Clinical and pathological	BC (blood)		BC (tumour)
characteristics	BRCA1 UU $\mathrm{+}$ BRCA2 UU ($n\mathrm{=}$ 55)	BRCA1 UU $\mathrm{+}$ BRCA2 MU ($n\mathrm{=}$ 10)	BRCA1 UU $\mathrm{+}$ BRCA2 UU ($n\mathrm{=}$ 31)	BRCA1 UU $\mathrm{+}$ BRCA2 MU ($n\mathrm{=}$ 17)
Age groups
Up to 50 years	26 (47.3%)	2 (20.0%)	18 (58.1%)	4 (23.5%)
After 50 years	29 (52.7%)	8 (80.0%)	13 (41.9%)	13 (76.5%)
$p$	0.20		0.046
Ki67 groups
Low (0%–15%)	10 (21.7%)	1 (10.0%)	9 (34,6%)	0 (0%)
Intermediate (16%–29%)	10 (21.7%)	5 (50.0%)	6 (23.1%)	5 (35.7%)
High ($⩾$ 30%)	26 (56.5%)	4 (40.0%)	11 (42.3%)	9 (64.3%)
$p$	0.33		0.035
Progesterone receptor
Negative	12 (21.8%)	6 (60.0%)	6 (19.4%)	7 (41.2%)
Positive	43 (78.2%)	4 (40.0%)	25 (80.6%)	10 (58.8%)
$p$ value	0.0359		0.18

M – methylated; U – unmethylated.